Therefore, although the administration of AAV-Hep-Glrx does not alter steatosis, this treatment can reduce NASH diet-induced hepatic apoptosis and fibrosis and improve liver function. Here, GLRX is linked to metabolic dysfunction-associated steatohepatitis.